Clinical Trial

Post-operative Analgesic Effect of Oral Nefopam

Study acronym: NefPO
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Primary knee arthroplasty by total prosthesis is a painful surgery, performed on patients with advanced gonarthrosis (stage III), thus already presenting hyperalgesia and hyperalgesia and allodynia. This terrain makes the risk of postoperative hyperalgesia but also of persistent postoperative risk of persistent post-surgical pain. Nefopam is a non-opioid centrally acting analgesic drug used as a part of multimodal analgesia. The opioid-sparing effect of nefopam is still controversial across various surgical procedures. In France nefopam is only available as a parenteral formulation; however it is often administered orally. There is currently no study addressing the efficacy of oral nefopam for the postoperative pain management including pain prevention. The investigators conduct a prospective, double-blinded randomized controlled study with the main objective to examine the effect of perioperative orally administered nefopam on postoperative pain after a total knee arthroplasty. Secondary objectives include the quantification of wound allodynia, analysis of adverse events, clinical outcomes, and a pharmacokinetic study of orally given nefopam (plasma and cerebrospinal fluid dosage).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2020-09-29; most recent amendment 2026-05-13.
Status change: Not Yet Recruiting → Recruiting 2022-01-17
Trial Details
NCT Number NCT04576078
Lead Sponsor Hospices Civils de Lyon
Conditions Postoperative Pain After a Total Knee Arthroplasty
Enrollment 50 participants
Start Date 2021-06-29
Primary Completion 2026-12-30 (estimated)
Study Completion 2027-05-15 (estimated)
Updated on ClinicalTrials.gov 2026-05-14